Host-Directed Therapies Based on Protease Inhibitors to Control Mycobacterium tuberculosis and HIV Coinfection DOI Creative Commons
Manoj Mandal, David Pires, José Miguel Azevedo‐Pereira

et al.

Microorganisms, Journal Year: 2025, Volume and Issue: 13(5), P. 1040 - 1040

Published: April 30, 2025

Despite continuous and extensive global efforts in the fight against tuberculosis (TB), this infectious disease continues to exert a tremendous burden on public health concerns deaths worldwide. TB, caused by bacterial species Mycobacterium tuberculosis, is highly frequent people living with HIV. The continuing epidemics of both chronic infections emergence antimicrobial resistance, as well lack effective diagnostic tools drug–drug interactions, pose major challenges these pathogens. Developing wide range host-directed therapies may improve treatment outcomes, helping alleviate morbidity mortality associated infections. In review, we discuss identification development new strategies based protease inhibitors their clinical relevance adjunctive treatment. context therapeutic agents novel mechanisms, selective inhibitors, including saquinavir (SQV) cystatins (CstC CstF), are valuable targets that provide solutions for controlling Mtb HIV coinfection.

Language: Английский

Host-Directed Therapies Based on Protease Inhibitors to Control Mycobacterium tuberculosis and HIV Coinfection DOI Creative Commons
Manoj Mandal, David Pires, José Miguel Azevedo‐Pereira

et al.

Microorganisms, Journal Year: 2025, Volume and Issue: 13(5), P. 1040 - 1040

Published: April 30, 2025

Despite continuous and extensive global efforts in the fight against tuberculosis (TB), this infectious disease continues to exert a tremendous burden on public health concerns deaths worldwide. TB, caused by bacterial species Mycobacterium tuberculosis, is highly frequent people living with HIV. The continuing epidemics of both chronic infections emergence antimicrobial resistance, as well lack effective diagnostic tools drug–drug interactions, pose major challenges these pathogens. Developing wide range host-directed therapies may improve treatment outcomes, helping alleviate morbidity mortality associated infections. In review, we discuss identification development new strategies based protease inhibitors their clinical relevance adjunctive treatment. context therapeutic agents novel mechanisms, selective inhibitors, including saquinavir (SQV) cystatins (CstC CstF), are valuable targets that provide solutions for controlling Mtb HIV coinfection.

Language: Английский

Citations

0